Cisulan Tablets

This product is an antitussive, expectorant and anti-infective drug. It is a compound preparation of sulfamethoxazole (SMZ), trimethoprim (TMP), pentoxyverine citrate and bromhexine hydrochloride. The mechanism of action is: SMZ acts on dihydrofolate synthase, interfering with the first step of folic acid synthesis, TMP acts on the second step of folic acid anabolism, selectively inhibiting the action of dihydrofolate reductase. The combination of the two can double-block the folic acid metabolism of bacteria. The synergistic antibacterial effect of this product is stronger than that of a single drug. Pentotheline citrate is a non-addictive antitussive drug with central and peripheral antitussive effects. Bromhexine hydrochloride has a strong effect of dissolving mucus.

This product is a compound preparation, and its components are: each tablet contains 0.2g of sulfamethoxazole, 40mg of trimethoprim, 6.25mg of pentoxyverine citrate, and 4mg of bromhexine hydrochloride.

This product is white tablets.

It can relieve cough, eliminate phlegm and reduce inflammation. It is used for acute and chronic upper respiratory tract infections and lung infections.

Oral administration: 2 tablets at a time, twice a day, double the dose for the first time, and reduce the dose for children.

1. Allergic reactions are common and may manifest as drug eruptions. In severe cases, exudative erythema multiforme, exfoliative dermatitis and epidermolysis bullosa atrophic dermatitis may occur. There are also serum sickness-like reactions such as photosensitivity, drug fever, joint and muscle pain, fever, etc. Anaphylactic shock is occasionally seen. 2. Occasionally, patients may experience serious adverse reactions such as interstitial nephritis or renal tubular necrosis. 3. Nausea, vomiting, decreased appetite, headache, fatigue, diarrhea, constipation, etc., generally mild symptoms. Occasionally, Clostridium difficile enteritis occurs, and the drug should be discontinued at this time. 4. Occasionally, thyroid enlargement and hypofunction occur. 5. Central nervous system toxicity may occasionally occur, manifested as mental confusion, disorientation, hallucinations, euphoria or depression. 6. Occasionally, aseptic meningitis may occur, with symptoms such as headache, stiff neck, nausea, etc. 7. There may be a slight irritation reaction to the gastric mucosa.

1. This product is contraindicated for those who are allergic to SMZ and TMP. 2. Since this product blocks the metabolism of folic acid, it can aggravate the folate deficiency in patients with megaloblastic anemia, so it is contraindicated for all patients with this disease. 3. This product is contraindicated for those with severe liver and kidney damage.

Precautions for children: 1. Infants under 2 months old are contraindicated to take this product. 2. The dosage for children should be reduced as appropriate. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited from taking this product. Precautions for the elderly: Not yet clear.

1. The combined use of urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. This product cannot be used in combination with para-aminobenzoic acid. 3. When the following drugs are used together with this product, their dosages need to be adjusted: oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. The combined use with bone marrow suppressive drugs may enhance the adverse reactions of such drugs to the hematopoietic system. 5. The long-term combined use of estrogen contraceptives with this product may reduce the contraceptive effect. 6. When used in combination with thrombolytic drugs, their potential toxic effects may be increased. 7. When used in combination with hepatotoxic drugs, the incidence of hepatotoxicity may be increased. 8. When used in combination with photosensitizing drugs, the incidence of photosensitization may be increased. 9. The need for vitamin K in patients receiving this product increases. 10. It should not be used in combination with methenamine. 11. This product can replace the plasma protein binding site of phenylbutazone, and when the two are used together, the effect of phenylbutazone can be enhanced. 12. When used in combination with sulfinpyrazone, the secretion and excretion of this product from the renal tubules is reduced, which can increase its blood concentration. 13. The TMP in this product can inhibit the metabolism of warfarin and enhance its anticoagulant effect. 14. The TMP in this product can increase nephrotoxicity when used in combination with cyclosporine. 15. When rifampicin is used in combination with this product, the clearance of TMP in this product can be significantly increased and the serum half-life can be shortened. 16. It is not suitable to be used in combination with anti-tumor drugs and 2,4-diaminopyrimidine drugs, nor is it suitable to use this product during the treatment of other folic acid antagonists. 17. It is not suitable to be used in combination with dapsone. 18. Avoid using it in combination with penicillins, because this product may interfere with the bactericidal effect of penicillins. 19. When used in combination with tetracycline antibiotics, it can increase the antibacterial efficacy.

Keep away from light and store in a sealed container.

Compound

Tentative 24 months

NORTHEAST Pharmaceutical Group Shenyang NO.1 Pharmaceutical Co., Ltd.

• Founded in:

  1989-01-25

• Address:

  No. 8 Kunming Lake Street, Shenyang Economic and Technological Development Zone

• Tax NO.:

  91210106242656694M

• Registered Funds:

  80 million yuan

• Website:

  Log in to view

• Email:

  Log in to view